Authors

The Leap Forward: Practical Gains for Pharma AI Use

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.

Clinical Guidance Isn’t Optional: Fixing Patient Support in a Fragmented Pharmacy System

With prescription care changing, it’s up to benefits providers to reinforce the value of human connection in a complex system.

Biopharma Needs a Health System Strategy to Secure Optimal Market Access

In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.

Rethinking Audience Modeling: AI, Regulations, & More

The intersection of artificial intelligence and direct-to-consumer advertising presents unprecedented opportunities and evolving challenges as regulations and technologies reshape the biopharma landscape.

The Leap Forward: Practical Gains for Pharma AI Use

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.

Artificial Intelligence Makes Possible a Multiomic Approach in Oncology Drug Discovery

While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates more quickly and efficiently with applications in target discovery, structure prediction, and drug optimization.

Using AI to Predict Launch Success

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global Investment

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

Stop Losing Patients at the Gate: The 24-Hour Window That Makes or Breaks Your Entire Hub Program

Pioneering pharma’s next era: What will define the leaders of 2035?

Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma

Your Phase III Clinical Protocol Is Your Initial Product Launch

How demand-driven development will help new products be more successful.

Actionable Insights at the Point of Care: A New Era in Provider Engagement

How pharma marketers can time brand messages to prescribers when it matters most.

Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for Executives

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.

Point of Care Lifts Reps Efforts

Point of Care and PatientPoint can improve the impact that your Pharma Reps are already having.

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

The End of the Rebate Era? What HR Leaders and Pharmacy Consultants Need to Know About Biosimilars

As the availability and utilization of ultra-high-cost, long-term specialty products such as GLP-1s and cell and gene therapies grows, HR decision-makers and pharmacy consultants must embrace a more value-oriented mindset where they can.

2025 Pharma Forecast: Four Pivotal Trends Revolutionizing Market Access Strategies

From Blockbusters to Black Holes: Pharma Launch Strategy in the Age of Technology and AI

A Brave New World: Implications of the IRA on Brand Strategy

Amid converging pharma pricing trends, such as those triggered by the Inflation Reduction Act, companies must adopt novel operational practices and strategic approaches in line with new parameters for success across a product’s lifecycle.

The Evolution of Healthcare Communication: Bridging the HCP-Patient Divide

Key trends in healthcare communication to build trust between healthcare providers and their patients.

The AI Force Multiplier: How AI Is Leveling the Playing Field for Small and Mid-Size Biotech

By giving small and mid-size biotechs access to real-world data and advanced analytics once reserved for large pharma, AI platforms are leveling the playing field by enabling lean teams to de-risk clinical strategy, strengthen fundraising narratives, and make faster, more confident decisions across the development lifecycle.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Strategic advantage: Optichannel engagement drives ROI across the product lifecycle

Your Phase III Clinical Protocol Is Your Initial Product Launch

How demand-driven development will help new products be more successful.

Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint

Recent policy shifts in these two influential health technology assessment markets signal a broader regional move toward faster, more innovation-friendly access frameworks.

Navigating Cross-Border Pharma Deals: Key Trends and Lessons Out of China

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

Transforming Life Sciences R&D: The Business Case for AI

Webinar Date/Time: Thu, Aug 14, 2025 3:30 PM EDT